Physician profile
Tiffany Hendrix
NPI 1982945416
$2,010.24
in general payments reported to CMS, 2019-2025
26 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $397 · 2023: $474 · 2024: $375 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.80 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $331.13 | 2022-2025 | |
| Astellas Pharma US INC | $192.80 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $109.06 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $91.72 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $86.90 | 2022-2024 | Injectafer |
| Organon LLC | $79.56 | 2022-2025 | Nexplanon |
| Exact Sciences Corporation | $67.17 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $58.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $52.95 | 2023-2025 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $50.77 | 2024-2025 | Myfembree |
| Agile Therapeutics, INC. | $46.64 | 2021-2022 | |
| Millicent US INC | $43.76 | 2025 | Femlyv |
| Coopersurgical, INC. | $43.39 | 2022-2025 | Paragard T 380a |
| Hologic Sales and Service, LLC | $42.79 | 2024-2025 | Fluent Fluid Management System, Aptima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $34.41 | 2021-2022 | |
| Myovant Sciences INC. | $33.59 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $30.08 | 2021 | |
| Avion Pharmaceuticals | $28.36 | 2021-2023 | Balcoltra |
| Pfizer INC. | $25.50 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $22.40 | 2023 | Bd Onclarity |
| Pharmacosmos Therapeutics INC. | $22.14 | 2022 | |
| Axonics, INC. | $19.92 | 2023 | Axonics, Bulkamid |
| Minerva Surgical, INC | $13.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.85 | 2023 | Seglentis |
| Althera Pharmaceuticals LLC | $9.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.